As vaccines for COVID-19 dash towards the finish line, companies have in parallel had to work at break-neck speed to scale up at-risk manufacturing of the candidates to ensure that they can be delivered quickly once approved.
Merck KGaA Exec On Innovating Vaccine Manufacturing To Tackle Outbreaks
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
